Zacks.com on MSN3d
JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer
Study investigators expect that J&J's combo drug can extend overall survival by at least a year over the current standard of ...
CURE3d
First-line Rybrevant Combo Extends Survival in Advanced Lung Cancer
First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.
PharmExec3d
Phase II Trial Shows Combination of Rybrevant Plus Lazcluze Significantly Reduces Moderate-to-Severe Skin, Nail Reactions in EGFR-Mutated NSCLC
Results from the COCOON study showed that Rybrevant plus Lacluze reduced grade 2 or higher dermatologic events by 50% ...
Nasdaq3d
JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer
J&J JNJ recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca’s AZN Tagrisso in first-line EGFR ...
pharmaphorum2d
J&J throws the gauntlet down to AZ with new survival data
Johnson & Johnson has been saying for some time that it thinks its combination of Rybrevant and Lazcluze is the best option for patients with EGFR-mutated non-small cell lung cancer (NSCLC ...
24/7 Wall St. on MSN4d
These 10 Stocks Have Increased Dividends For Over 60 Consecutive Years. Should You Buy Them Now?
Dividend King stocks can succumb to management complacency or over conservative policies that can dull a competitive edge, ...